Related Experiment Video
Updated: Aug 20, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Sudden Vision Loss Secondary to Optic Nerve Infiltration as a Presenting Symptom of Metastatic Lung Adenocarcinoma
M M Shamim1, M Whaley1, H Rana2
1Department of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences (UAMS) Medical Center, Little Rock, Arkansas, USA.
Purpose:
To report a rare case of left-sided metastatic optic nerve infiltration and right-sided choroidal mass with exudative retinal detachment caused by EGFR exon 19 deletion positive non-small-cell lung adenocarcinoma that responded to targeted therapy with osimertinib (EGFR-TKI). Our patient demonstrated an excellent response with reduced size of the metastatic choroidal mass of the right orbit and improved visual acuity, in addition to systemic disease control.
Case:
A 66-year-old male patient with a history of diabetes mellitus, hypertension, and tobacco use presented with sudden vision loss in the left eye secondary to optic nerve infiltration and subacute vision loss in the right eye secondary to exudative retinal detachment from a choroidal metastasis. He was found to have a right lung mass, multiple metastatic pulmonary nodules, and liver and bone metastases. Biopsy from a mediastinal lymph node confirmed the diagnosis of metastatic lung adenocarcinoma. He was found to have exon 19 deletion on next-generation sequencing. We treated him with local radiation therapy to the left eye and systemic osimertinib (EGFR-TKI).
Conclusion:
To our knowledge, our case is the first report of a patient who initially presented with acute vision loss and was found to have metastatic retrobulbar optic nerve infiltration in one eye and metastatic choroidal lesion with exudative retinal detachment in the fellow eye secondary to lung adenocarcinoma. Due to the rarity of this condition, literature regarding effective treatment is scarce. Our patient demonstrated significant improvement in visual acuity and resolution of exudative retinal detachment in the right eye following osimertinib treatment and radiation therapy to the left eye. Further investigation into the role of tyrosine kinase inhibitors and radiation therapy in treating intraocular metastasis involving the optic nerve is needed.
Insights
This case study highlights a rare instance of lung cancer spreading to the eye, causing vision loss. Targeted therapy with osimertinib (EGFR-TKI) successfully treated the ocular metastasis and improved vision.
Area of Science:
- Ophthalmology
- Oncology
- Genetics
Background:
- Non-small-cell lung adenocarcinoma (NSCLC) can metastasize to the eye.
- Ocular metastasis from NSCLC is rare, particularly involving the optic nerve and choroid.
- EGFR exon 19 deletions are a common mutation in NSCLC, often responsive to targeted therapies.
Observation:
- A 66-year-old male presented with acute vision loss in the left eye and subacute vision loss in the right eye.
- Ophthalmic examination revealed left optic nerve infiltration and a right choroidal mass with exudative retinal detachment.
- Systemic evaluation identified metastatic NSCLC with an EGFR exon 19 deletion.
Findings:
- The patient received radiation therapy to the left eye and systemic osimertinib (an EGFR tyrosine kinase inhibitor).
- Treatment resulted in a significant reduction in the size of the metastatic choroidal mass.
- Visual acuity improved, and exudative retinal detachment resolved in the right eye, alongside systemic disease control.
Implications:
- This case demonstrates the efficacy of targeted therapy (osimertinib) in managing rare intraocular metastases from NSCLC.
- Osimertinib, in combination with radiation, offers a potential treatment strategy for ocular involvement in EGFR-mutated NSCLC.
- Further research is warranted to explore the role of TKIs and radiation in treating optic nerve and choroidal metastases.
Related Concept Videos
Photoreceptors and Visual Pathways
Glaucoma: Overview
Angle Closure Glaucoma: Treatment

